Literature DB >> 3658352

Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors.

C L Shields1, J A Shields, M B Shields, J J Augsburger.   

Abstract

A survey of 2704 eyes with intraocular tumors in patients who were evaluated on the Oncology Service at Wills Eye Hospital showed that 126 of the tumor-containing eyes (5%) had tumor-induced elevated intraocular pressure (IOP) at the time of diagnosis of the tumor. Of the 2111 eyes with uveal melanomas, secondary IOP elevation was present in 55 (3%). Secondary IOP elevation was present in 7% of eyes with iris melanoma, 17% with ciliary body melanoma, and 2% with choroidal melanoma. The most common mechanism of elevated IOP was tumor invasion of the angle in the case of iris melanomas, pigment dispersion and tumor invasion of the angle in the case of ciliary body melanomas, and iris neovascularization in the case of choroidal melanomas. Of the 256 eyes with uveal metastases, secondary IOP elevation was found in 12 eyes (5%). Secondary IOP elevation was present in 64% of eyes with iris metastases, 67% with ciliary body metastases, and 1% with choroidal metastases. The most common mechanism of elevated IOP was tumor invasion of the angle in the case of iris and ciliary body metastases, and angle closure in the case of choroidal metastases. There were 303 eyes with retinoblastoma, 17% of which had elevated IOP which was secondary to iris neovascularization in 70% of cases and to an angle closure without neovascularization in 27%. Several other intraocular tumors including lymphoma, leukemia, medulloepithelioma, melanocytoma, and adenoma of the iris pigment epithelium were occasionally associated with secondary elevated IOP.

Entities:  

Mesh:

Year:  1987        PMID: 3658352     DOI: 10.1016/s0161-6420(87)33537-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

1.  Adenoma of ciliary pigment epithelium: a case series.

Authors:  S Dinakaran; P A Rundle; M A Parsons; I G Rennie
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

2.  Pupil sparing excision of an atypical iris melanocytoma induces remission of secondary glaucoma.

Authors:  J C Zhao; D N Zacks; E S Gragoudas; L R Pasquale
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

3.  Massive choroidal effusion and painful secondary glaucoma from underlying uveal melanoma.

Authors:  Juan C Iturralde; Carlos Bianciotto; Sara E Lally; Michael Krasnow; Carol L Shields
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-13       Impact factor: 3.117

4.  Uveal melanoma masquerading as pigment dispersion glaucoma.

Authors:  David L Johnson; Michael M Altaweel; Aneesh Neekhra; Suresh R Chandra; Daniel M Albert
Journal:  Arch Ophthalmol       Date:  2008-06

5.  [Chronic uveitis with secondary glaucoma?].

Authors:  I Huebert; A Muacevic; A Kampik; K H Eibl-Lindner
Journal:  Ophthalmologe       Date:  2013-07       Impact factor: 1.059

6.  Anaplastic large cell lymphoma involving anterior segment of the eye.

Authors:  Choul Yong Park; Sang Won Hwang; Do Yeun Kim; Hee Jin Huh; Jong-Hyun Oh
Journal:  Korean J Ophthalmol       Date:  2014-01-21

7.  Ring melanoma--a rare cause of refractory glaucoma.

Authors:  V Lee; I A Cree; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1999-02       Impact factor: 4.638

8.  Factors associated with elevated intraocular pressure in eyes with iris melanoma.

Authors:  C L Shields; M A Materin; J A Shields; E Gershenbaum; A D Singh; A Smith
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

9.  Orbital Extension of an Unsuspected Choroidal Melanoma Presumably through an Aqueous Tube Shunt.

Authors:  Hayyam Kiratli; İrem Koç; Berçin Tarlan
Journal:  Ocul Oncol Pathol       Date:  2015-11-25

10.  Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K A Baez; J Cater; P V De Potter
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.